<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" class="marks" width="670" height="466" viewBox="0 0 670 466"><rect width="670" height="466" fill="white"/><g fill="none" stroke-miterlimit="10" transform="translate(84,5)"><g class="mark-group role-frame root" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0.5,0.5h300v420h-300Z" stroke="#ddd"/><g><g class="mark-group role-axis" aria-hidden="true"><g transform="translate(0.5,420.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-grid" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(46,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(92,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(138,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(185,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(231,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(277,0)" x2="0" y2="-420" stroke="#ddd" stroke-width="1" opacity="1"/></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis titled 'Total Score' for a linear scale with values from 0 to 65"><g transform="translate(0.5,420.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(46,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(92,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(138,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(185,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(231,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(277,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="start" transform="translate(0,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0</text><text text-anchor="middle" transform="translate(46.15384615384615,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">10</text><text text-anchor="middle" transform="translate(92.3076923076923,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">20</text><text text-anchor="middle" transform="translate(138.46153846153848,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">30</text><text text-anchor="middle" transform="translate(184.6153846153846,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">40</text><text text-anchor="middle" transform="translate(230.76923076923077,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">50</text><text text-anchor="middle" transform="translate(276.92307692307696,18)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">60</text></g><g class="mark-rule role-axis-domain" pointer-events="none"><line transform="translate(0,0)" x2="300" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(150,34)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Total Score</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'GeneSymbol' for a discrete scale with 21 values: SCO2, FBXO6, LAP3, SAMD9L, PARP12, ending with STAT1"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,10)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,30)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,50)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,70)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,90)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,110)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,130)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,150)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,170)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,190)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,210)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,230)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,250)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,270)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,290)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,310)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,330)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,350)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,370)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,390)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,410)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,13.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">SCO2</text><text text-anchor="end" transform="translate(-7,33.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">FBXO6</text><text text-anchor="end" transform="translate(-7,53.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">LAP3</text><text text-anchor="end" transform="translate(-7,73.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">SAMD9L</text><text text-anchor="end" transform="translate(-7,93.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">PARP12</text><text text-anchor="end" transform="translate(-7,113.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">GBP4</text><text text-anchor="end" transform="translate(-7,133.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">DDX60</text><text text-anchor="end" transform="translate(-7,153.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">IFI35</text><text text-anchor="end" transform="translate(-7,173.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">DHX58</text><text text-anchor="end" transform="translate(-7,193.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">IFIT5</text><text text-anchor="end" transform="translate(-7,213.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">ZBP1</text><text text-anchor="end" transform="translate(-7,233.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">PARP14</text><text text-anchor="end" transform="translate(-7,253.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">GBP5</text><text text-anchor="end" transform="translate(-7,273.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">IFIH1</text><text text-anchor="end" transform="translate(-7,293.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">TRIM22</text><text text-anchor="end" transform="translate(-7,313.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">IFIT2</text><text text-anchor="end" transform="translate(-7,333.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">GBP1</text><text text-anchor="end" transform="translate(-7,353.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">IRF7</text><text text-anchor="end" transform="translate(-7,373.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">OAS2</text><text text-anchor="end" transform="translate(-7,393.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">DDX58</text><text text-anchor="end" transform="translate(-7,413.5)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">STAT1</text></g><g class="mark-rule role-axis-domain" pointer-events="none"><line transform="translate(0,0)" x2="0" y2="420" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-67.0205078125,210) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">GeneSymbol</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-rect role-mark marks" role="graphics-object" aria-roledescription="rect mark container"><path aria-label="score: 10; GeneSymbol: DDX58; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,381h46.15384615384615v18h-46.15384615384615Z" fill="#de2d26"/><path aria-label="score: 3.66666666667; GeneSymbol: DDX58; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M46.15384615384615,381h16.923076923076927v18h-16.923076923076927Z" fill="#fc9272"/><path aria-label="score: 5.66666666667; GeneSymbol: DDX58; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M63.07692307692308,381h26.153846153846146v18h-26.153846153846146Z" fill="#fee5d9"/><path aria-label="score: 8.66666666667; GeneSymbol: DDX58; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M89.23076923076923,381h40v18h-40Z" fill="#756bb1"/><path aria-label="score: 1.66666666667; GeneSymbol: DDX58; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M129.23076923076923,381h7.692307692307708v18h-7.692307692307708Z" fill="#74c476"/><path aria-label="score: 6.33333333333; GeneSymbol: DDX58; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M136.92307692307693,381h29.230769230769226v18h-29.230769230769226Z" fill="#c7e9c0"/><path aria-label="score: 3.33333333333; GeneSymbol: DDX58; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M166.15384615384616,381h15.384615384615387v18h-15.384615384615387Z" fill="#c994c7"/><path aria-label="score: 8.33333333333; GeneSymbol: DDX58; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M181.53846153846155,381h38.46153846153848v18h-38.46153846153848Z" fill="#dd1c77"/><path aria-label="score: 8.66666666667; GeneSymbol: DDX60; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,121h40v18h-40Z" fill="#de2d26"/><path aria-label="score: 3.66666666667; GeneSymbol: DDX60; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M40,121h16.92307692307692v18h-16.92307692307692Z" fill="#fc9272"/><path aria-label="score: 3; GeneSymbol: DDX60; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M56.92307692307692,121h13.846153846153854v18h-13.846153846153854Z" fill="#fee5d9"/><path aria-label="score: 7; GeneSymbol: DDX60; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M70.76923076923077,121h32.30769230769231v18h-32.30769230769231Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: DDX60; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M103.07692307692308,121h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 5.33333333333; GeneSymbol: DDX60; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M112.3076923076923,121h24.6153846153846v18h-24.6153846153846Z" fill="#c7e9c0"/><path aria-label="score: 1; GeneSymbol: DDX60; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M136.9230769230769,121h4.615384615384642v18h-4.615384615384642Z" fill="#c994c7"/><path aria-label="score: 5.66666666667; GeneSymbol: DDX60; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M141.53846153846155,121h26.153846153846104v18h-26.153846153846104Z" fill="#dd1c77"/><path aria-label="score: 8.66666666667; GeneSymbol: DHX58; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,161h40v18h-40Z" fill="#de2d26"/><path aria-label="score: 3.66666666667; GeneSymbol: DHX58; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M40,161h16.92307692307692v18h-16.92307692307692Z" fill="#fc9272"/><path aria-label="score: 3.66666666667; GeneSymbol: DHX58; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M56.92307692307692,161h16.92307692307692v18h-16.92307692307692Z" fill="#fee5d9"/><path aria-label="score: 7; GeneSymbol: DHX58; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M73.84615384615384,161h32.30769230769232v18h-32.30769230769232Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: DHX58; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M106.15384615384616,161h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 5.33333333333; GeneSymbol: DHX58; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M115.38461538461539,161h24.615384615384613v18h-24.615384615384613Z" fill="#c7e9c0"/><path aria-label="score: 1.33333333333; GeneSymbol: DHX58; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M140,161h6.15384615384616v18h-6.15384615384616Z" fill="#c994c7"/><path aria-label="score: 6; GeneSymbol: DHX58; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M146.15384615384616,161h27.69230769230768v18h-27.69230769230768Z" fill="#dd1c77"/><path aria-label="score: 2.66666666667; GeneSymbol: FBXO6; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,21h12.307692307692308v18h-12.307692307692308Z" fill="#de2d26"/><path aria-label="score: 1.66666666667; GeneSymbol: FBXO6; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M12.307692307692308,21h7.692307692307692v18h-7.692307692307692Z" fill="#fc9272"/><path aria-label="score: 1; GeneSymbol: FBXO6; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M20,21h4.615384615384617v18h-4.615384615384617Z" fill="#fee5d9"/><path aria-label="score: 4.66666666667; GeneSymbol: FBXO6; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M24.615384615384617,21h21.538461538461537v18h-21.538461538461537Z" fill="#756bb1"/><path aria-label="score: 0.666666666667; GeneSymbol: FBXO6; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M46.15384615384615,21h3.07692307692308v18h-3.07692307692308Z" fill="#74c476"/><path aria-label="score: 3.66666666667; GeneSymbol: FBXO6; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M49.23076923076923,21h16.923076923076913v18h-16.923076923076913Z" fill="#c7e9c0"/><path aria-label="score: 1; GeneSymbol: FBXO6; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M66.15384615384615,21h4.615384615384627v18h-4.615384615384627Z" fill="#c994c7"/><path aria-label="score: 2.66666666667; GeneSymbol: FBXO6; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M70.76923076923077,21h12.307692307692307v18h-12.307692307692307Z" fill="#dd1c77"/><path aria-label="score: 6.66666666667; GeneSymbol: GBP1; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,321h30.769230769230774v18h-30.769230769230774Z" fill="#de2d26"/><path aria-label="score: 9; GeneSymbol: GBP1; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M30.769230769230774,321h41.53846153846155v18h-41.53846153846155Z" fill="#fc9272"/><path aria-label="score: 4.66666666667; GeneSymbol: GBP1; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M72.30769230769232,321h21.538461538461547v18h-21.538461538461547Z" fill="#fee5d9"/><path aria-label="score: 8; GeneSymbol: GBP1; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M93.84615384615387,321h36.923076923076906v18h-36.923076923076906Z" fill="#756bb1"/><path aria-label="score: 2.66666666667; GeneSymbol: GBP1; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M130.76923076923077,321h12.30769230769232v18h-12.30769230769232Z" fill="#74c476"/><path aria-label="score: 5.33333333333; GeneSymbol: GBP1; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M143.0769230769231,321h24.615384615384613v18h-24.615384615384613Z" fill="#c7e9c0"/><path aria-label="score: 1.66666666667; GeneSymbol: GBP1; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M167.6923076923077,321h7.692307692307679v18h-7.692307692307679Z" fill="#c994c7"/><path aria-label="score: 6.66666666667; GeneSymbol: GBP1; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M175.3846153846154,321h30.769230769230774v18h-30.769230769230774Z" fill="#dd1c77"/><path aria-label="score: 5.66666666667; GeneSymbol: GBP4; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,101h26.153846153846157v18h-26.153846153846157Z" fill="#de2d26"/><path aria-label="score: 6.33333333333; GeneSymbol: GBP4; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M26.153846153846157,101h29.23076923076923v18h-29.23076923076923Z" fill="#fc9272"/><path aria-label="score: 3.66666666667; GeneSymbol: GBP4; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M55.38461538461539,101h16.92307692307692v18h-16.92307692307692Z" fill="#fee5d9"/><path aria-label="score: 6.66666666667; GeneSymbol: GBP4; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M72.3076923076923,101h30.769230769230774v18h-30.769230769230774Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: GBP4; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M103.07692307692308,101h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 5; GeneSymbol: GBP4; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M112.3076923076923,101h23.07692307692308v18h-23.07692307692308Z" fill="#c7e9c0"/><path aria-label="score: 1; GeneSymbol: GBP4; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M135.3846153846154,101h4.615384615384613v18h-4.615384615384613Z" fill="#c994c7"/><path aria-label="score: 5; GeneSymbol: GBP4; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M140,101h23.076923076923066v18h-23.076923076923066Z" fill="#dd1c77"/><path aria-label="score: 6.66666666667; GeneSymbol: GBP5; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,241h30.769230769230774v18h-30.769230769230774Z" fill="#de2d26"/><path aria-label="score: 7.33333333333; GeneSymbol: GBP5; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M30.769230769230774,241h33.84615384615384v18h-33.84615384615384Z" fill="#fc9272"/><path aria-label="score: 4.33333333333; GeneSymbol: GBP5; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M64.61538461538461,241h20v18h-20Z" fill="#fee5d9"/><path aria-label="score: 8.33333333333; GeneSymbol: GBP5; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M84.61538461538461,241h38.46153846153845v18h-38.46153846153845Z" fill="#756bb1"/><path aria-label="score: 2.33333333333; GeneSymbol: GBP5; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M123.07692307692307,241h10.769230769230774v18h-10.769230769230774Z" fill="#74c476"/><path aria-label="score: 5; GeneSymbol: GBP5; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M133.84615384615384,241h23.076923076923094v18h-23.076923076923094Z" fill="#c7e9c0"/><path aria-label="score: 1.33333333333; GeneSymbol: GBP5; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M156.92307692307693,241h6.15384615384616v18h-6.15384615384616Z" fill="#c994c7"/><path aria-label="score: 6.66666666667; GeneSymbol: GBP5; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M163.0769230769231,241h30.769230769230774v18h-30.769230769230774Z" fill="#dd1c77"/><path aria-label="score: 8; GeneSymbol: IFI35; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,141h36.92307692307693v18h-36.92307692307693Z" fill="#de2d26"/><path aria-label="score: 5; GeneSymbol: IFI35; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M36.92307692307693,141h23.076923076923073v18h-23.076923076923073Z" fill="#fc9272"/><path aria-label="score: 3; GeneSymbol: IFI35; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M60,141h13.846153846153854v18h-13.846153846153854Z" fill="#fee5d9"/><path aria-label="score: 7; GeneSymbol: IFI35; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M73.84615384615385,141h32.30769230769231v18h-32.30769230769231Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: IFI35; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M106.15384615384616,141h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 6; GeneSymbol: IFI35; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M115.38461538461539,141h27.692307692307708v18h-27.692307692307708Z" fill="#c7e9c0"/><path aria-label="score: 1; GeneSymbol: IFI35; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M143.0769230769231,141h4.615384615384613v18h-4.615384615384613Z" fill="#c994c7"/><path aria-label="score: 5; GeneSymbol: IFI35; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M147.6923076923077,141h23.076923076923066v18h-23.076923076923066Z" fill="#dd1c77"/><path aria-label="score: 9.33333333333; GeneSymbol: IFIH1; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,261h43.07692307692308v18h-43.07692307692308Z" fill="#de2d26"/><path aria-label="score: 3; GeneSymbol: IFIH1; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M43.07692307692308,261h13.846153846153847v18h-13.846153846153847Z" fill="#fc9272"/><path aria-label="score: 5.33333333333; GeneSymbol: IFIH1; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M56.92307692307693,261h24.61538461538462v18h-24.61538461538462Z" fill="#fee5d9"/><path aria-label="score: 8; GeneSymbol: IFIH1; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M81.53846153846155,261h36.92307692307692v18h-36.92307692307692Z" fill="#756bb1"/><path aria-label="score: 2.33333333333; GeneSymbol: IFIH1; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M118.46153846153847,261h10.76923076923076v18h-10.76923076923076Z" fill="#74c476"/><path aria-label="score: 5; GeneSymbol: IFIH1; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M129.23076923076923,261h23.076923076923066v18h-23.076923076923066Z" fill="#c7e9c0"/><path aria-label="score: 2.33333333333; GeneSymbol: IFIH1; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M152.3076923076923,261h10.769230769230802v18h-10.769230769230802Z" fill="#c994c7"/><path aria-label="score: 7; GeneSymbol: IFIH1; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M163.0769230769231,261h32.30769230769229v18h-32.30769230769229Z" fill="#dd1c77"/><path aria-label="score: 9.33333333333; GeneSymbol: IFIT2; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,301h43.07692307692308v18h-43.07692307692308Z" fill="#de2d26"/><path aria-label="score: 5; GeneSymbol: IFIT2; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M43.07692307692308,301h23.07692307692308v18h-23.07692307692308Z" fill="#fc9272"/><path aria-label="score: 5; GeneSymbol: IFIT2; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M66.15384615384616,301h23.07692307692308v18h-23.07692307692308Z" fill="#fee5d9"/><path aria-label="score: 7.66666666667; GeneSymbol: IFIT2; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M89.23076923076924,301h35.3846153846154v18h-35.3846153846154Z" fill="#756bb1"/><path aria-label="score: 3; GeneSymbol: IFIT2; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M124.61538461538464,301h13.84615384615384v18h-13.84615384615384Z" fill="#74c476"/><path aria-label="score: 6; GeneSymbol: IFIT2; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M138.46153846153848,301h27.69230769230768v18h-27.69230769230768Z" fill="#c7e9c0"/><path aria-label="score: 2; GeneSymbol: IFIT2; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M166.15384615384616,301h9.230769230769226v18h-9.230769230769226Z" fill="#c994c7"/><path aria-label="score: 6.66666666667; GeneSymbol: IFIT2; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M175.3846153846154,301h30.769230769230774v18h-30.769230769230774Z" fill="#dd1c77"/><path aria-label="score: 9; GeneSymbol: IFIT5; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,181h41.53846153846154v18h-41.53846153846154Z" fill="#de2d26"/><path aria-label="score: 4; GeneSymbol: IFIT5; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M41.53846153846154,181h18.46153846153846v18h-18.46153846153846Z" fill="#fc9272"/><path aria-label="score: 4.33333333333; GeneSymbol: IFIT5; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M60,181h20v18h-20Z" fill="#fee5d9"/><path aria-label="score: 7; GeneSymbol: IFIT5; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M80,181h32.30769230769231v18h-32.30769230769231Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: IFIT5; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M112.3076923076923,181h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 5.66666666667; GeneSymbol: IFIT5; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M121.53846153846153,181h26.153846153846175v18h-26.153846153846175Z" fill="#c7e9c0"/><path aria-label="score: 1.66666666667; GeneSymbol: IFIT5; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M147.6923076923077,181h7.692307692307651v18h-7.692307692307651Z" fill="#c994c7"/><path aria-label="score: 6; GeneSymbol: IFIT5; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M155.38461538461536,181h27.692307692307708v18h-27.692307692307708Z" fill="#dd1c77"/><path aria-label="score: 10; GeneSymbol: IRF7; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,341h46.15384615384615v18h-46.15384615384615Z" fill="#de2d26"/><path aria-label="score: 3; GeneSymbol: IRF7; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M46.15384615384615,341h13.846153846153847v18h-13.846153846153847Z" fill="#fc9272"/><path aria-label="score: 6; GeneSymbol: IRF7; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M60,341h27.692307692307693v18h-27.692307692307693Z" fill="#fee5d9"/><path aria-label="score: 8.66666666667; GeneSymbol: IRF7; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M87.6923076923077,341h40v18h-40Z" fill="#756bb1"/><path aria-label="score: 4; GeneSymbol: IRF7; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M127.6923076923077,341h18.461538461538467v18h-18.461538461538467Z" fill="#74c476"/><path aria-label="score: 6.33333333333; GeneSymbol: IRF7; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M146.15384615384616,341h29.230769230769226v18h-29.230769230769226Z" fill="#c7e9c0"/><path aria-label="score: 2; GeneSymbol: IRF7; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M175.3846153846154,341h9.230769230769226v18h-9.230769230769226Z" fill="#c994c7"/><path aria-label="score: 7.66666666667; GeneSymbol: IRF7; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M184.6153846153846,341h35.38461538461536v18h-35.38461538461536Z" fill="#dd1c77"/><path aria-label="score: 3; GeneSymbol: LAP3; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,41h13.846153846153847v18h-13.846153846153847Z" fill="#de2d26"/><path aria-label="score: 2; GeneSymbol: LAP3; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M13.846153846153847,41h9.23076923076923v18h-9.23076923076923Z" fill="#fc9272"/><path aria-label="score: 1; GeneSymbol: LAP3; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M23.076923076923077,41h4.615384615384617v18h-4.615384615384617Z" fill="#fee5d9"/><path aria-label="score: 5; GeneSymbol: LAP3; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M27.692307692307693,41h23.07692307692308v18h-23.07692307692308Z" fill="#756bb1"/><path aria-label="score: 1.66666666667; GeneSymbol: LAP3; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M50.769230769230774,41h7.692307692307686v18h-7.692307692307686Z" fill="#74c476"/><path aria-label="score: 3.33333333333; GeneSymbol: LAP3; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M58.46153846153846,41h15.384615384615394v18h-15.384615384615394Z" fill="#c7e9c0"/><path aria-label="score: 1.33333333333; GeneSymbol: LAP3; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M73.84615384615385,41h6.153846153846146v18h-6.153846153846146Z" fill="#c994c7"/><path aria-label="score: 3; GeneSymbol: LAP3; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M80,41h13.84615384615384v18h-13.84615384615384Z" fill="#dd1c77"/><path aria-label="score: 9.66666666667; GeneSymbol: OAS2; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,361h44.61538461538461v18h-44.61538461538461Z" fill="#de2d26"/><path aria-label="score: 5.33333333333; GeneSymbol: OAS2; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M44.61538461538461,361h24.615384615384627v18h-24.615384615384627Z" fill="#fc9272"/><path aria-label="score: 5; GeneSymbol: OAS2; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M69.23076923076924,361h23.076923076923066v18h-23.076923076923066Z" fill="#fee5d9"/><path aria-label="score: 8.33333333333; GeneSymbol: OAS2; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M92.3076923076923,361h38.46153846153847v18h-38.46153846153847Z" fill="#756bb1"/><path aria-label="score: 3; GeneSymbol: OAS2; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M130.76923076923077,361h13.846153846153868v18h-13.846153846153868Z" fill="#74c476"/><path aria-label="score: 7; GeneSymbol: OAS2; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M144.61538461538464,361h32.30769230769229v18h-32.30769230769229Z" fill="#c7e9c0"/><path aria-label="score: 2; GeneSymbol: OAS2; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M176.92307692307693,361h9.230769230769226v18h-9.230769230769226Z" fill="#c994c7"/><path aria-label="score: 7.33333333333; GeneSymbol: OAS2; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M186.15384615384616,361h33.84615384615387v18h-33.84615384615387Z" fill="#dd1c77"/><path aria-label="score: 7.66666666667; GeneSymbol: PARP12; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,81h35.38461538461539v18h-35.38461538461539Z" fill="#de2d26"/><path aria-label="score: 3.66666666667; GeneSymbol: PARP12; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M35.38461538461539,81h16.923076923076927v18h-16.923076923076927Z" fill="#fc9272"/><path aria-label="score: 2.33333333333; GeneSymbol: PARP12; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M52.307692307692314,81h10.769230769230774v18h-10.769230769230774Z" fill="#fee5d9"/><path aria-label="score: 6.33333333333; GeneSymbol: PARP12; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M63.07692307692309,81h29.23076923076922v18h-29.23076923076922Z" fill="#756bb1"/><path aria-label="score: 1.33333333333; GeneSymbol: PARP12; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M92.3076923076923,81h6.15384615384616v18h-6.15384615384616Z" fill="#74c476"/><path aria-label="score: 5; GeneSymbol: PARP12; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M98.46153846153847,81h23.076923076923066v18h-23.076923076923066Z" fill="#c7e9c0"/><path aria-label="score: 2.66666666667; GeneSymbol: PARP12; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M121.53846153846153,81h12.307692307692307v18h-12.307692307692307Z" fill="#c994c7"/><path aria-label="score: 4.66666666667; GeneSymbol: PARP12; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M133.84615384615384,81h21.53846153846152v18h-21.53846153846152Z" fill="#dd1c77"/><path aria-label="score: 7; GeneSymbol: PARP14; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,221h32.30769230769231v18h-32.30769230769231Z" fill="#de2d26"/><path aria-label="score: 5; GeneSymbol: PARP14; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M32.30769230769231,221h23.07692307692308v18h-23.07692307692308Z" fill="#fc9272"/><path aria-label="score: 3.33333333333; GeneSymbol: PARP14; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M55.38461538461539,221h15.384615384615387v18h-15.384615384615387Z" fill="#fee5d9"/><path aria-label="score: 8; GeneSymbol: PARP14; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M70.76923076923077,221h36.923076923076934v18h-36.923076923076934Z" fill="#756bb1"/><path aria-label="score: 2; GeneSymbol: PARP14; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M107.69230769230771,221h9.230769230769226v18h-9.230769230769226Z" fill="#74c476"/><path aria-label="score: 5.66666666667; GeneSymbol: PARP14; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M116.92307692307693,221h26.15384615384616v18h-26.15384615384616Z" fill="#c7e9c0"/><path aria-label="score: 4; GeneSymbol: PARP14; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M143.0769230769231,221h18.461538461538424v18h-18.461538461538424Z" fill="#c994c7"/><path aria-label="score: 7; GeneSymbol: PARP14; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M161.53846153846152,221h32.30769230769235v18h-32.30769230769235Z" fill="#dd1c77"/><path aria-label="score: 8; GeneSymbol: SAMD9L; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,61h36.92307692307693v18h-36.92307692307693Z" fill="#de2d26"/><path aria-label="score: 3; GeneSymbol: SAMD9L; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M36.92307692307693,61h13.846153846153847v18h-13.846153846153847Z" fill="#fc9272"/><path aria-label="score: 2; GeneSymbol: SAMD9L; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M50.769230769230774,61h9.230769230769226v18h-9.230769230769226Z" fill="#fee5d9"/><path aria-label="score: 7; GeneSymbol: SAMD9L; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M60,61h32.30769230769231v18h-32.30769230769231Z" fill="#756bb1"/><path aria-label="score: 1; GeneSymbol: SAMD9L; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M92.3076923076923,61h4.615384615384627v18h-4.615384615384627Z" fill="#74c476"/><path aria-label="score: 5; GeneSymbol: SAMD9L; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M96.92307692307693,61h23.076923076923066v18h-23.076923076923066Z" fill="#c7e9c0"/><path aria-label="score: 0.666666666667; GeneSymbol: SAMD9L; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M120,61h3.0769230769230944v18h-3.0769230769230944Z" fill="#c994c7"/><path aria-label="score: 6; GeneSymbol: SAMD9L; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M123.0769230769231,61h27.692307692307708v18h-27.692307692307708Z" fill="#dd1c77"/><path aria-label="score: 0.666666666667; GeneSymbol: SCO2; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,1h3.076923076923077v18h-3.076923076923077Z" fill="#de2d26"/><path aria-label="score: 0.666666666667; GeneSymbol: SCO2; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M3.076923076923077,1h3.076923076923077v18h-3.076923076923077Z" fill="#fc9272"/><path aria-label="score: 0.666666666667; GeneSymbol: SCO2; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M6.153846153846154,1h3.0769230769230775v18h-3.0769230769230775Z" fill="#fee5d9"/><path aria-label="score: 2.66666666667; GeneSymbol: SCO2; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M9.230769230769232,1h12.307692307692305v18h-12.307692307692305Z" fill="#756bb1"/><path aria-label="score: 0.666666666667; GeneSymbol: SCO2; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M21.538461538461537,1h3.07692307692308v18h-3.07692307692308Z" fill="#74c476"/><path aria-label="score: 2.33333333333; GeneSymbol: SCO2; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M24.615384615384617,1h10.76923076923077v18h-10.76923076923077Z" fill="#c7e9c0"/><path aria-label="score: 0; GeneSymbol: SCO2; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M35.38461538461539,1h0v18h0Z" fill="#c994c7"/><path aria-label="score: 1.33333333333; GeneSymbol: SCO2; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M35.38461538461539,1h6.153846153846153v18h-6.153846153846153Z" fill="#dd1c77"/><path aria-label="score: 10; GeneSymbol: STAT1; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,401h46.15384615384615v18h-46.15384615384615Z" fill="#de2d26"/><path aria-label="score: 9.66666666667; GeneSymbol: STAT1; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M46.15384615384615,401h44.615384615384606v18h-44.615384615384606Z" fill="#fc9272"/><path aria-label="score: 8; GeneSymbol: STAT1; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M90.76923076923076,401h36.923076923076934v18h-36.923076923076934Z" fill="#fee5d9"/><path aria-label="score: 9.33333333333; GeneSymbol: STAT1; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M127.6923076923077,401h43.07692307692308v18h-43.07692307692308Z" fill="#756bb1"/><path aria-label="score: 5.33333333333; GeneSymbol: STAT1; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M170.76923076923077,401h24.615384615384613v18h-24.615384615384613Z" fill="#74c476"/><path aria-label="score: 7; GeneSymbol: STAT1; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M195.3846153846154,401h32.30769230769232v18h-32.30769230769232Z" fill="#c7e9c0"/><path aria-label="score: 4.66666666667; GeneSymbol: STAT1; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M227.6923076923077,401h21.538461538461547v18h-21.538461538461547Z" fill="#c994c7"/><path aria-label="score: 8.66666666667; GeneSymbol: STAT1; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M249.23076923076925,401h39.99999999999997v18h-39.99999999999997Z" fill="#dd1c77"/><path aria-label="score: 9; GeneSymbol: TRIM22; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,281h41.53846153846154v18h-41.53846153846154Z" fill="#de2d26"/><path aria-label="score: 5.66666666667; GeneSymbol: TRIM22; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M41.53846153846154,281h26.153846153846168v18h-26.153846153846168Z" fill="#fc9272"/><path aria-label="score: 4; GeneSymbol: TRIM22; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M67.69230769230771,281h18.461538461538453v18h-18.461538461538453Z" fill="#fee5d9"/><path aria-label="score: 8; GeneSymbol: TRIM22; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M86.15384615384616,281h36.923076923076934v18h-36.923076923076934Z" fill="#756bb1"/><path aria-label="score: 2.66666666667; GeneSymbol: TRIM22; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M123.0769230769231,281h12.30769230769232v18h-12.30769230769232Z" fill="#74c476"/><path aria-label="score: 6.66666666667; GeneSymbol: TRIM22; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M135.38461538461542,281h30.769230769230745v18h-30.769230769230745Z" fill="#c7e9c0"/><path aria-label="score: 1.66666666667; GeneSymbol: TRIM22; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M166.15384615384616,281h7.692307692307679v18h-7.692307692307679Z" fill="#c994c7"/><path aria-label="score: 6.33333333333; GeneSymbol: TRIM22; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M173.84615384615384,281h29.230769230769255v18h-29.230769230769255Z" fill="#dd1c77"/><path aria-label="score: 9; GeneSymbol: ZBP1; Statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M0,201h41.53846153846154v18h-41.53846153846154Z" fill="#de2d26"/><path aria-label="score: 4.66666666667; GeneSymbol: ZBP1; Statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M41.53846153846154,201h21.538461538461547v18h-21.538461538461547Z" fill="#fc9272"/><path aria-label="score: 3.33333333333; GeneSymbol: ZBP1; Statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="bar" d="M63.07692307692309,201h15.38461538461538v18h-15.38461538461538Z" fill="#fee5d9"/><path aria-label="score: 8; GeneSymbol: ZBP1; Statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="bar" d="M78.46153846153847,201h36.92307692307692v18h-36.92307692307692Z" fill="#756bb1"/><path aria-label="score: 2.33333333333; GeneSymbol: ZBP1; Statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="bar" d="M115.38461538461539,201h10.769230769230774v18h-10.769230769230774Z" fill="#74c476"/><path aria-label="score: 5.66666666667; GeneSymbol: ZBP1; Statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="bar" d="M126.15384615384616,201h26.153846153846132v18h-26.153846153846132Z" fill="#c7e9c0"/><path aria-label="score: 1.66666666667; GeneSymbol: ZBP1; Statements: g. Known drug target" role="graphics-symbol" aria-roledescription="bar" d="M152.3076923076923,201h7.692307692307708v18h-7.692307692307708Z" fill="#c994c7"/><path aria-label="score: 6.66666666667; GeneSymbol: ZBP1; Statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="bar" d="M160,201h30.769230769230745v18h-30.769230769230745Z" fill="#dd1c77"/></g><g class="mark-group role-legend" role="graphics-symbol" aria-roledescription="legend" aria-label="Symbol legend titled 'Statements' for fill color with 8 values: a. Association with type I interferon responses, b. Association with type II interferon responses, c. Association with type III interferon responses, d. Relevance to circulating leukocytes immune biology, e. Used as a biomarker in clinical settings, ending with h. Therapeutically relevant for immune system diseases"><g transform="translate(318,0)"><path class="background" aria-hidden="true" d="M0,0h263v118h-263Z" pointer-events="none"/><g><g class="mark-group role-legend-entry"><g transform="translate(0,16)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-group role-scope" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#de2d26" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">a. Association with type I interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,13)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#fc9272" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">b. Association with type II interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,26)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#fee5d9" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">c. Association with type III interferon responses</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,39)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#756bb1" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">d. Relevance to circulating leukocytes immune biology</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,52)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#74c476" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">e. Used as a biomarker in clinical settings</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,65)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#c7e9c0" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">f. Potential value as a blood transcriptional biomarker</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,78)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#c994c7" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">g. Known drug target</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,91)"><path class="background" aria-hidden="true" d="M0,0h262.7724609375v11h-262.7724609375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(6,6)" d="M-5,-5h10v10h-10Z" fill="#dd1c77" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(16,9)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">h. Therapeutically relevant for immune system diseases</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-text role-legend-title" pointer-events="none"><text text-anchor="start" transform="translate(0,9)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Statements</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g></g></svg>